Comparison of Ketorolac Tromethamine with Other Injectable Nonsteroidal Anti-Inflammatory Drugs for Pain-on-Injection and Muscle Damage in the Rat

Abstract

The local tolerance of ketorolac tromethamine (Toradol®, Syntex) was compared with that of four other injectable nonsteroidal anti-inflammatory drugs (NSAIDs) (diclofenac sodium, piroxicam, ketoprofen, and metamizol magnesium) in the rat paw-lick/muscle irritation assay as described previously,¹ All drugs were tested at concentrations approved for clinical use. After subplantar (footpad) injection, ketorolac produced virtually no pain-on-injection as assessed by the number of paw-lick/lift responses during a 15 min observation period. The other NSAIDs produced slight to moderate paw-lick/lift responses. Redness and swelling at the injection site were less severe for ketorolac than for the other NSAIDs, After intramuscular (i.m.) injection, all of the. NSAIDs produced some degree of muscle damage, as assessed histopathologically 24 h after injection. The lesions, consisting primarily of muscle degeneration, were less severe for ketorolac than for the other NSAIDs. Ketorolac and metamizol produced the smallest elevations in serum creatine kinase, as measured 2 h after i.m. dosing, not significantly different from isotonic saline. Overall, ketorolac was better tolerated in the assay than the other injectable NSAIDs, thereby suggesting the possibility of improved local tolerance on clinical use.

Get full access to this article

View all access options for this article.

References

Chellman GJ , Faurot, GF, Lollini LO & McCullough TE. Raw paw-lick/muscle irritation model for evaluating parenteral formulations for pain-on-injection and muscle damage. Fundamental and Applied Toxicology 1990; 15: 697-709.

Rooks WH II , Maloney PJ , Shott LD et al. The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt. Drugs Under Experimental and Clinical Research 1985; 11: 479-92.

Litvak KM & McEvoy GK Ketorolac, an injectable nonnarcotic analgesic. Clinical Pharmacy 1990; 9: 921-35.

Surber C. & Sucker H. Tissue tolerance of intramuscular injectables and plasma enzyme activities in rats. Pharmaceutical Research 1987; 4: 490-94.

SAS/STAT User's Guide. Version 6, Fourth Edition, Volume 1, SAS Institute, Inc., Cary, NC USA, 1990.

Vaccarino V. , Sirtori CR & Bufalino L. Local and systemic tolerability of piroxicam after intramuscular administration in healthy volunteers. Current Therapeutic Research 1989; 45: 1-13.

Baroni L. , Grossi E. & Trombetta N. Multicenter investigation of the use of injectable diclofenac in painful conditions: Analysis of clinical data pertaining to 1873 patients. Clinica Terapeutica 1983; 106: 447-56.

Wiseman RL & Kilgour M. Intramuscular piroxicam, a new dosage form, in the treatment of acute musculoskeletal disorders. The Journal of International Medical Research 1985; 13: 255-62.

Katona G. & Burgos-Vargas R. Clinical experiences with the intramuscular injection of tiaprofenic acid in rheumatic diseases, with particular emphasis on time of onset and duration of the analgesic effect. Drugs 1988; 35: 72-80.

10.

Garcia Alonso F. , Gonzalez de Suso MJ , Lopez Alvarez M. , Palop R. , Lucena MI & Marin R. Comparative study of the efficacy of dipyrone, diclofenac sodium and pethidine in acute renal colic. European Journal of Clinical Pharmacology 1991; 40: 543-46.

11.

Yee JP , Koshiver JE , Allbon C. & Brown CR Comparison of intramuscular ketorolac tromethamine and morphine sulfate for analgesia of pain after major surgery. Pharmacotherapy 1986; 6: 253-61.